Exelixis (EXEL) Gross Profit Growth (1y) (2013 - 2026)

Exelixis (EXEL) Gross Profit Growth (1y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Profit Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 41.37%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 7.76%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 16.94%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 68.41%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Exelixis 14.44 Bn 13.66 Bn 590.86 Mn 10.18%

Historic Data

Download Data
DateValue
Apr 3, 2026 10.18%
Jan 2, 2026 4.64%
Oct 3, 2025 10.91%
Jul 4, 2025 -11.42%
Apr 4, 2025 32.75%
Jan 3, 2025 19.41%
Sep 27, 2024 15.24%
Jun 28, 2024 37.02%
Mar 29, 2024 2.41%
Dec 29, 2023 12.23%
Sep 29, 2023 14.31%
Jun 30, 2023 11.38%
Mar 31, 2023 15.08%
Sep 30, 2022 25.24%
Jul 1, 2022 9.63%
Apr 1, 2022 33.36%
Oct 1, 2021 42.35%
Jul 2, 2021 47.96%
Apr 2, 2021 18.11%
Oct 2, 2020 -15.82%